No one wants to experience breast cancer, but knowing the best treatment path can make a significant difference when faced with this challenge. The American Society of Clinical Oncology (ASCO) recently updated guidelines to help doctors and patients choose the most effective treatments based on the specific characteristics of the cancer. Let's break down these guidelines into simpler terms.
Who Do These Guidelines Apply To?
These guidelines are designed for women diagnosed with early-stage invasive breast cancer. Early-stage means the cancer has not spread far within the body. These recommendations help doctors and patients decide on additional (adjuvant) treatments after surgery, like hormone therapy or chemotherapy.
What Are Biomarkers?
Think of biomarkers as clues found in the cancer cells that can tell us how aggressive the cancer is and how it might respond to treatments. The ASCO guidelines focus on which biomarkers to check for making treatment decisions.
The Tests and What They Tell Us
Extended Therapy Decisions
After 5 years of hormone therapy, the decision to continue treatment depends on the risk of cancer returning. Tests like the Breast Cancer Index (BCI) and clinical treatment score after 5 years (CTS5) can help estimate this risk and guide decisions on continuing hormone therapy.
HER2-Positive or Triple-Negative Breast Cancer
For those with HER2-positive or triple-negative breast cancer, the current multiparameter gene expression or protein assays (like Oncotype DX, MammaPrint, etc.) are not recommended for guiding treatment decisions.
Emerging Biomarkers
New areas of research like tumor-infiltrating lymphocytes (TILs), PD-L1 testing, circulating tumor cells (CTC), and circulating tumor DNA (ctDNA) show promise, but they're not yet recommended for guiding treatment decisions in early-stage breast cancer.
The Bottom Line
Understanding the specific characteristics of breast cancer can help tailor treatment to each individual, potentially improving outcomes and minimizing unnecessary side effects. These guidelines are a step towards more personalized cancer care, offering hope for more effective and targeted treatments. Be sure to ask your oncologist if you qualify for any of these testing options.
You must be logged in to post a comment.
The information provided by Cancer Help Desk is not a substitute for medical advice, diagnosis, treatment, or other health care services. Always seek the advice of your physician or other qualified healthcare provider and talk with your healthcare provider about any questions you may have.
Cancer Help Desk is a qualified 501(c)(3) tax-exempt organization and all donations are tax deductible to the fullest extent allowed by tax laws. Tax Identification Number: 92-3967197.